Pfizer shares experienced a significant surge on the NSE, climbing as high as ₹4,995.85 on May 20, 2025, following a strong earnings report. The pharmaceutical company announced an impressive 85% year-on-year increase in net profit for the fourth quarter, which ended on March 31, 2025.
Net profit reached ₹331 crore, a substantial rise from ₹179 crore in the same quarter of the previous year. This performance boosted investor confidence, further fueled by the declaration of a total dividend of ₹165 per share for FY25.
The dividend includes a final dividend of ₹35 per share (350%), a special dividend of ₹100 per share (1000%) to commemorate Pfizer's 75th year in India, and an additional dividend of ₹30 per share (300%) as a result of gains on asset transfers. Revenue from operations for Q4FY25 increased by 8% to ₹592 crore, compared to ₹546.63 crore in the previous year. The company has set July 9, 2025, as the record date for dividend eligibility. EBITDA also saw growth, rising 20% to ₹227 crore, with the EBITDA margin expanding from 34.75% to 38.4%.